Infant Bacterial Therapeutics’ Focus Areas

Product Pipeline

IBT’s current pipeline includes four development programs:


Prevention of necrotizing enterocolitis (NEC) & improved sustained
feeding tolerance (SFT) of premature infants


Neonatal treatment of gastroschisis


Prevention of retinopathy of prematurity (ROP)


Prevention of antibiotic resistant hospital acquired infections
caused by vancomycin-resistant enterococci (VRE)

IBT’s current lead drug candidate is IBP-9414 is the first ever New Biological Entity (NBE) developed to prevent necrotizing enterocolitis in premature infants and improve their sustained feeding tolerance. IBP-9414 is currently being evaluated in a global phase III study involving 2158 infants with a birthweight between 500g-1500g, the Connection Study (more information can be found at Identifier: NCT03978000). IBP-9414 contains the active substance Lactobacillus reuteri, a human bacterial strain naturally present in breast milk. Read more about the research involving Connection Study, NEC, and SFT in the IBP-9414 specific section.